Time and date
December 4th, 2025
7PM – 8PM
Redefining the emergency response in anaphylaxis

Join our live and interactive webinar and learn more about the advances in anaphylaxis care.

This webinar will be led by two allergy experts: Prof. George du Toit and Dr. Shelley Dua.

Why attend?

Expert Guidance: Gain insights from two allergy experts

Gain insights from two allergy experts Emergency response in anaphylaxis: Learn about the current treatment, the unmet need and the advances in anaphylaxis care

Patient empowerment: Increase patients’ confidence in acting when anaphylaxis occurs.

Speakers
Prof. George du Toit
Consultant in paediatric allergy
Professor George du Toit is Professor of Paediatric Allergy at a leading London NHS Trust, and at the new Allergy Centre of Excellence. His clinical research focuses on the prevention, diagnosis, and treatment of food allergy, drug allergy, chronic urticaria, and exercise-induced anaphylaxis.
Dr. Shelley Dua
Consultant in Allergy
Dr Shelley Dua is a Consultant in Adult Allergy at Cambridge University Hospitals NHS Trust. After qualifying in Medicine from the University of Edinburgh, she completed her clinical training in London and Cambridge and received a PhD from the University of Cambridge. Shelley was a lead investigator on the TRACE study which explored how exercise and sleep deprivation influence the threshold and severity of peanut allergic reactions. Her key interests include food allergy, anaphylaxis, and allergen risk management. She previously co-chaired the European Task Force for Food Allergy at the Institute of Life Sciences.
What to expect?

During this 1-hour webinar, you’ll gain a better understanding of anaphylaxis treatment, the importance and the current unmet need. You will also be updated about a new treatment option for the emergency response in anaphylaxis and receive tips & tricks on how to empower patients.

You will also be able to ask questions to our speakers about anything anaphylaxis related.

This promotional webinar is developed and funded by ALK.

November 2025
GB-EURn-2500172